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Abstract
Recombinant adenoassociated viral vectors (rAAV) have proven to be excellent candidates for gene therapy clinical
applications. Recent results showed that cellular immunity to AAV represents a major challenge facing the clinical use of
systemic administration of these vectors. Interestingly, no preclinical animal model has previously fully reproduced the
clinical findings. The aim of the present work was to enhance the T cell immune response against AAV capsid in mice by the
administration of a rAAV expressing the immunostimulatory cytokine IL-12. Our results indicate that although IL-12
expression enhanced the AAV capsid-specific immune response it failed to eliminate transduced hepatocytes and long-term
expression was achieved. We found that AAV-mediated transgene expression is altered by IL-12-induced liver inflammation.
However, IL-12 expression has no effect over preexisting AAV-mediated transgene expression. IL-12 down-regulates AAV
mediated transgene expression via induction of IFN-c production by NK and T cells, but without altering the transduction
efficiency measured by viral genomes. Our results indicate that liver inflammation affects the formation of transcriptionally
active AAV vector genomes through an unknown mechanism that can be avoided by the use of DNA-demethylating or anti-
inflammatory agents.
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Introduction
AAV is a parvovirus, which is a family of small, non-enveloped
viruses containing a single-stranded linear DNA genome of about
5 kb; the wild-type virus is replication-deficient, requiring a helper
virus for multiplication. In humans, AAV has not been found to be
pathogenic. This fact, along with the tendency for the genomes of
recombinant AAV (rAAV) vectors to remain as episomal
concatemers rather than integrating into the host genome, makes
AAV a relatively safe gene transfer vector for testing in the clinic
[1]. AAV have been used successfully for in vivo gene transfer in
numerous preclinical animal models of human disease. Recently,
AAV vectors have also generated long-term clinical benefit in
patients suffering from Leber’s congenital amaurosis [2]. However,
in patients with hemophilia B, hepatic gene transfer with AAV2
and AAV8 expressing Factor IX induced specific cellular immune
responses against the viral capsid that in the case of the AAV2,
resulted in loss of expression of Factor IX. In the case of AAV8,
the administration of a short course of high dose steroids blocked
the immune response and allowed clinical efficacy [3] [4]. None of
the preclinical animal models used to test these vectors predicted
the outcome in humans, and the low immunogenicity of AAV
vectors has been thought to be one of main features of AAV
vectors. For example, activation of innate immunity following
AAV vector administration is very low and transient [5], although
significant differences have been reported depending on the target
organ. AAV intramuscular injection induces signaling through the
Toll-like receptor 9 (TLR9)–myeloid differentiation factor 88
(MyD88) pathway to induce type I IFN and this activation is
critical for CD8+ T cell responses to the AAV capsid and for the
loss of transgene expression in vivo [6]. However, in the liver
although AAV vectors have been shown to induce the expression
of chemokines and cytokines, the response is transient and occurs
at a higher threshold titers compared to adenovirus vectors [7]. It
is well known that innate immunity plays an important role in the
subsequent T cell responses against viruses, since it provides
activation signals that recruit and activate antigen presenting cells
as well as T and B cell immune responses. IL-12 has the capacity
to activate both innate and adaptive immune response [8]. IL-
12 has been used as an adjuvant for vaccination and for the
treatment of tumors, leading to the generation of specific CTLs
[9]. With the aim of inducing a T cell response against the AAV
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capsid in mice, in the present study we have constructed a
recombinant AAV expressing the cytokine IL-12 in the liver,
constitutively or after tetracycline induction [9]. Mice were treated
with IL-12 expression vectors alone or together with an AAV
vector expressing luciferase as reporter gene. Although AAV
specific T cell responses could be induced by the expression of IL-
12, long-term transgene expression was nonetheless achieved,
indicating that the T cell response failed to eliminate transgene
expression. Furthermore, we found that AAV-mediated expression
is altered by IL-12-induced liver inflammation; in particular, the
IFN-c produced by NK and T cells alters the formation of AAV
transcriptionally active forms but has no effect on previously
established transgene expression. This effect can be reversed by
the administration of DNA-demethylating and anti-inflammatory
agents.
Results
AAV-mediated Sustained Liver Specific IL-12 Expression
C57BL/6 female mice (n = 5) were intravenously injected with
different doses of an AAV8 expressing IL12 under the control of a
liver specific promoter, AAV8-IL12, 1.56109, 56109, 1.561010,
561010, 1.561011, 561011, 1.561012, or 561012 viral genomes
(vg)/kg. Mice receiving the higher doses died between day three
and seven after vector administration due to IL-12 toxicity,
characterized by a significant loss of weight and diarrhea. Only the
mice receiving the lowest doses, 56109, and 1.56109 vg/kg,
survived with IL-12 serum concentrations close to the ELISA
detection limit or undetectable (Fig. 1A). However, IFN-c
expression, the main mediator of IL12 activity, could be detected
in serum (Fig. 1B). Twenty-one days after AAV8-IL12 injection at
a dose of 1.56109 vg/kg animals were sacrificed and the degree of
inflammatory response in the liver was analyzed. High expression
levels of TNF-a and IL-1b were detected in the liver (Fig. 1C)
together with significant inflammatory cellular infiltrates (Fig. 1D).
IL-12 Expression Enhances the T–cell Response Against
the Viral Capsid but does not Result in Elimination of AAV
Mediated Transgene Expression
In order to determine if AAV8-IL12 can induce a T cell specific
immune response able to eliminate AAV8 transduced cells, we
coadministered the AAV8-IL12 together with an AAV8 vector
expressing luciferase (AAV8-luc) that allowed us to monitor long-
term transgene expression in vivo. C57BL/6 mice were injected
with AAV8-luc at a dose of 561011 vg/kg and AAV8-IL12 at a
dose of 1.56109 vg/kg or with AAV8-luc alone (561011 vg/kg).
As shown in Fig. 1E, sustained luciferase expression could be
detected in both groups of animals. The immune response against
peptides derived from the AAV8 capsid protein were analyzed in
these animals, however, due to the sustained IL-12 expression, no
differences in IFN-c production were observed between non-
stimulated or peptide-stimulated lymphocytes due to the sustained
expression of IFN-c induced by IL-12. To eliminate the
background, an AAV8 expressing IL-12 upon tetracycline admin-
istration was used (AAV8-tetON-IL12). Mice received an intra-
venous injection of AAV8-tetON-IL12 twenty days later IL-12
expression was induced by tetracycline administration during
seven days. The immune response was analyzed two weeks after
tetracycline removal, once the IFN-c disappeared from serum. As
a positive control mice were immunized with an adenoviral vector
expressing AAV8 capsid protein (Ad5-Cap8) and 10 days later the
animals were sacrificed [10]. ELISpot analysis revealed that
inducible IL-12 expression increased T cell response against
peptides derived from the AAV8 capsid protein (Fig. 1F). The
response against a previously described H2b epitope [10] induced
by AAV8-tetON-IL12/AAV8-luc is lower in comparison to the
one induced by Ad5-Cap8. However, the total number of IFN-c
producing cells after stimulation with the peptide pools covering
the whole capsid protein is very similar (Fig. 1F). Interestingly, the
pools of peptides that induce IFN-c production in mice treated
with AAV8-tetON-IL12+AAV8-luc are different from pools
recognized by T cells induced by the adenovirus expressing the
AAV8 capsid VP1 protein, suggesting that antigen presentation is
different when the capsid protein is expressed in a target cell or
when it is endocytosed by antigen presenting cells (Fig. 1F).
IL-12 Expression Significantly Downregulates AAV
Mediated Transgene Expression
As shown in Fig. 1E, IL-12 expression does not eliminate but
significantly downregulates luciferase expression and the effect is
maintained over time. To further characterize the effect of IL-
12 on transgene expression C57BL/6 mice were injected with the
IL12- and the luciferase-encoding vectors as previously described,
and luciferase expression was analyzed at 1, 4, 7, and 14 days after
viral injection. No significant differences were observed at day 1
between the two groups (Fig. 2A). At day 4 the group of animals
that received both vectors showed a significantly lower level of
luciferase expression than the animals receiving luciferase alone.
The differences between the two groups increased with time
(Fig. 2A), and at day 14 luciferase expression values were tenfold
lower in the group of animals receiving IL-12 and luciferase
compared to the animals receiving luciferase alone.
Mice were sacrificed at day 14 and viral genome and luciferase
mRNA expression levels were analyzed by quantitative PCR
(qPCR), and luciferase activity was determined in liver extracts. As
shown in Fig. 2B, the number of viral genomes was the same in
both groups, while luciferase mRNA levels (Fig. 2B) and luciferase
activity (Fig. 2C) were significantly lower in the animals expressing
IL-12, reflecting the in vivo expression data. Furthermore, no
elevation in liver transaminase levels was observed (Fig. 2D). Our
results indicate that the lower levels of transgene expression in the
group of mice expressing IL-12 it is not due to the elimination of
AAV transduced hepatocytes but rather IL-12 inhibits vector
expression at a transcriptional level.
IL-12 Expression Induces IFN-c Production by NK and T
Cells, Resulting in Downregulation of AAV-mediated
Expression
IFN-c is the main mediator of many of the IL-12 biological
activity. To analyze the mechanism(s) responsible for the
downregulation of AAV-mediated gene expression, mice deficient
in IFN-c receptor a molecule were injected with AAV8-luc or
AAV8-luc+AAV8-IL12. As shown in Fig. 3A, no differences were
observed in luciferase expression between the two groups
indicating that IFN-c is one of the main mediators of the
downregulation of AAV mediated gene expression. To analyze the
types of cells involved in IFN-c production RAG2/2 mice
(lacking T, B, and NKT cells), RAG2/2 cc2/2 mice (lacking T,
B, NKT and NK cells), CD1d deficient mice (lacking NKT cells)
were injected with AAV8-luc or AAV8-luc+AAV8-IL12 and
luciferase expression was analyzed. Significant differences in
luciferase expression were observed between the group no treated
or treated with IL-12 when the mice were RAG2/2 mice
(Fig. 3B) or CD1d mice (Fig. 3D) but no when the mice were
RAG2/2 cc2/2 (Fig. 3C), suggesting a role for NK cells. For a
full elucidation of the role of NK cells, mice were depleted of NK
cells using and anti-NK1.1 antibody and treated with AAV8-luc or
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AAV8-luc+AAV8-IL12 (Fig. 3E). The analysis of luciferase
expression showed significant differences between the two groups
indicating that both NK and T cells play a role in IL-12 mediated
inhibition of transgene expression. Since IFN-c is the main
mediator of IL-12 inhibitory activity we next analyzed the
production of IFN-c. All the animals produced IFN-c after vector
injection except RAG-cc2/2 mice, which correlates with the
absence of differences in luciferase expression (Fig.S1).
Administration of the DNA Demethylating Agent, 5-AZA,
but not the Histone Deacetylase Inhibitor, TSA, Reverts
the IFN-c Inhibitory Effect
In previous work it has been shown that IFN-c downregulates
gene expression after hepatic administration of a plasmid or a
gutless adenovirus carrying IL-12, and that a class I/II histone
deacetylase inhibitor, was able to rescue liver-specific promoter
Figure 1. AAV8-IL-12 induces liver inflammation, enhances immune response against AAV8 but do not eliminate transduced
hepatocytes. C57BL/6 female mice (n = 5) received intravenously (IV) different doses of AAV8-IL12 vector and IL-12 A) and IFN-c B) concentration in
serum was analyzed by ELISA at different time points after vector injection. C) C57BL/6 female were IV injected with AAV8-IL-12 or AAV8-luc vectors
at a dose of 1.56109 vg/kg, 21 days after injection TNFa and IL-1b expression levels were analyzed in the liver by RT qPCR. D) Hematoxilin and eosin
staining of liver sections. E) Animals were injected with an AAV8-luc vector at a dose of 2.561011 vg/kg with or without coadministration of an AAV8-
IL12 vector at a dose of 1.56109 vg/kg. Luciferase expression in the liver was followed for 38 days by in vivo bioluminescence imaging and
quantification is represented as photons/second. F) C57BL/6 female mice received the AAV8-tetON-IL12 vector together with an AAV8-luc vector, or
AAV8-luc vector alone, or an adenoviral vector expressing AAV8 capsid protein (Ad5-Cap8) or saline. Twenty days after vector injection, animals
receiving AAV8-tetON-IL12 and AAV8-luc or AAV8-luc alone were treated with doxycycline (Dox) to induce IL-12 for 7 days expression and the
immune response was analyzed 14 days after Tet removal. Animals receiving Ad5-Cap8 were sacrificed 10 days after vector injection. Splenocytes
obtained from these mice were stimulated with different pools of peptides derived from the AAV8 VP1 capsid protein, the H2b peptide previously
described for the AAV8 capsid protein, NSLANPGIA [10], or PMA plus ionomycin as positive control.
doi:10.1371/journal.pone.0067748.g001
Effect of Liver Inflammation over AAV Transduction
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e67748
activity [11]. To test the role of histone acetylation and DNA
methylation in IFN-c mediated AAV transgene expression
downregulation, mice receiving AAV8-IL12 in combination with
AAV8-luc or with AAV8-luc alone were treated with the histone
deacetylase inhibitor TSA, the demethylating agent 5-AZA, or
vehicle. Due to the toxicity of 5-AZA long-term treatment animals
were sacrificed 7 days after vector injection. As shown in Fig. 4, no
differences were observed in luciferase expression between the
groups receiving IL-12 or not when the mice were treated with 5-
AZA while significant differences were detected in the TSA and
vehicle treated groups. These results suggest that a DNA
methylation modification is affecting AAV transcriptional activity
or the formation of transcriptionally active forms.
Treatment with Anti-inflammatory Agents Reverses the
Inhibitory Effect of IL-12
In order to determine if the IL-12 inhibitory effect over AAV
mediated transcription can be reversed by the administration of
anti-inflammatory agent; mice were treated with AAV8-IL12 in
combination with AAV8-luc or with AAV8-luc alone. The anti-
inflammatory reagent dexamethasone was administered before
and after the administration of the vector (as described in
methods). Luciferase expression was analyzed at days, 1, 4 and 7
after vector injection. No differences were observed between the
two groups indicating that corticoid treatment counteracted the
inhibitory effect of IL-12 induced inflammation (Fig. 5). The
analysis of IFN-c production in these animals showed that
dexamethasone treatment significantly reduced its production
(data not shown).
Figure 2. IL-12 down-regulates AAV mediated gene expression without reducing the number of viral genomes. C57BL/6 mice (n = 5)
received 2.561011 vg/kg of AAV8-luc vector alone or in combination with 1.56109 vg/kg of AAV8-IL12 vector. A) Luciferase expression levels were
analyzed in both groups of animals at days 1, 4, 7, and 14 using a Xenogen in vivo luminometer. Luciferase expression was quantified and
represented as photons/second. The data are shown as mean 6 standard deviation (SD). The differences in luciferase expression were statistically
evaluated by Student t test (**p,0.01). B) Animals were sacrificed at day 14. Total DNA and RNA were isolated from liver and vector genome copies
and luciferase messenger RNA (mRNA) copies were determined using a q-PCR specific for luciferase, normalized to GADPH copy numbers. Values
correspond to the mean copy number from five animals. C) The levels of luciferase activity (relative light units, RLUs) were determined in liver
homogenates and were normalized to protein content (RLU/mg). The data are shown as mean 6 SEM. D) Serum transaminases were analyzed
14 days after vector injection. The data are shown as mean 6 standard deviation (SD). Each experiment was repeated three times.
doi:10.1371/journal.pone.0067748.g002
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Figure 3. IFN-c produced by IL12-activated NK/T cells is the main mediator of AAV-mediated transgene expression
downregulation. A) IFN-cR deficient mice. B) RAG deficient mice. C) RAG cc deficient mice D) CD1d deficient E) C57BL/6 mice depleted or not
of NK cells; received 2.561011 vg/kg of AAV8-luc vector alone or in combination with 1.56109 vg/kg of AAV8-IL12 vector. As previously described,
luciferase expression levels were analyzed in both groups of animals at days 1, 4, 7, and 14 using a Xenogen in vivo luminometer. Luciferase
expression was quantified and represented as photons/second. The data are shown as mean 6 standard deviation (SD). The differences in luciferase
expression were statistically evaluated by Student t test (**p,0.01).
doi:10.1371/journal.pone.0067748.g003
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IL12-induced Liver Inflammation has No Effect Over
Established AAV-mediated Gene Expression
To further characterize the effect of IFN-c induction over AAV-
mediated transgene expression we administered first an AAV5
vector expressing luciferase under the control of a liver specific
promoter (AAV5-Luc) at a dose of 2.561013 vg/kg and, when
luciferase expression reached stable expression (21 days after
vector injection), mice were treated with AAV8-IL12 or an AAV8
expressing the red fluorescent protein as control (AAV8-iRFP) at a
dose of 1.56109 vg/kg. As shown in Fig. 6A, luciferase expression
was unaltered in both groups indicating that once the AAV
genomes are stabilized in the hepatocyte their expression is not
affected by IL-12-induced inflammation. Animals receiving
AAV8-IL12 showed IFN-c in serum indicating the AAV8
infection was not neutralized by anti-AAV5 antibodies (Fig. 6B).
Mice were sacrificed at day 14 and viral genome and luciferase
mRNA expression levels were analyzed by quantitative (qPCR)
and luciferase activity was determined in liver extracts, supporting
in vivo results (Fig. 6C).
Discussion
The initial goal of this experimental work was to develop a small
animal model in which AAV-mediated liver transduction is
eliminated by cellular immune response against viral capsid, in
an effort to reproduce the findings in the hemophilia clinical trials
in which patients developed a T cell immune response against the
AAV capsid protein, that resulted in the elimination of transduced
hepatocytes [3] [4].
One of the major advantages of AAV vectors is their
comparatively low immunogenicity profile, particularly the fact
that they elicit only limited inflammatory responses, at least in
experimental animal models. In fact the activation of the innate
immune response due to TLR2 and TLR9 activation after
recognition of AAV genome and capsid has been shown to be very
modest [12]. In an attempt to activate the innate immune system
and to induce the maturation antigen presenting cells (APCs) in
the presence of AAV viral particles we constructed an AAV viral
vector expressing IL-12, which is a potent activator of innate and
adaptive immune responses. In fact, IL-12 gene transfer into
tumors has been shown to induce the generation of specific CTLs
and tumor rejection [9]. Here we showed that the systemic
administration of very low doses of an AAV serotype 8 virus
expressing IL-12 under the control of a liver specific promoter
induces a strong inflammatory response in the liver, with
production of inflammatory cytokines including IFN-c, TNF-a
or IL-1b and presence of inflammatory infiltrates (Fig. 1D). No
cytokine production was detected when the reporter virus was
administered alone at high doses. Furthermore, ELISpot analysis
showed that IL-12 expression enhances the immune response
against AAV8 capsid derived peptides. In fact the total number of
IFN-c producing cells after stimulation with the peptide pools
covering the whole capsid protein is similar to the one induced by
immunization with an adenovirus expressing AAV8 capsid
proteins (Ad5-Cap8) [10]. Interestingly, the pool of peptides
recognized after Ad5-Cap8 immunization or AAV8-teON-IL12
were different suggesting a different processing of the capsid.
These differences might be due to the fact that when using Ad5-
Cap8 the antigen is endogenously expressed, processed and
presented in APCs, while after AAV administration the AAV
capsid proteins must be taken up exogenously and loaded in MHC
Figure 4. DNA demethylating agents but not histone acetylation inhibition revert the IFN-c inhibitory effect. C57BL/6 mice received
2.561011 vg/kg of AAV8-luc vector alone or in combination with 1.56109 vg/kg of AAV8-IL12 vector. One group of 5 mice treated with AAV8-luc or
AAV8-luc in combination with AAV8-IL12 received 59-Azacytidine (AZA) intraperitoneally at a dose of 1 mg/kg every 24 hours starting the day of
vector injection. A second group of 5 mice treated with AAV8-luc or AAV8-luc in combination with AAV8-IL12 received 2 mg/kg of trichostatin A
(TSA) were injected IP every 48 hours starting the day of vector injection. A third group of animals received only vector injection. Luciferase
expression levels were analyzed in both groups of animals at days 1, 4, and 7 using a Xenogen in vivo luminometer, experiments could not be
performed at longer time points due to the toxicity of 5-AZA long term treatment. Luciferase expression was quantified and represented as photons/
second. The data are shown as mean 6 standard deviation (SD). The differences in luciferase expression were statistically evaluated by Student t test
(**p,0.01).
doi:10.1371/journal.pone.0067748.g004
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class I molecules throughout a process known as cross-presenta-
tion.
Unexpectedly, long-term transgene expression could be
achieved after the administration of AAV expressing IL-12
indicating that neither the inflammatory reaction induced by IL-
12, nor the immune response induced against AAV capsid proteins
or the transgene, were able to eliminate AAV-transduced
hepatocytes. Our results correlate with previous studies in which
it was shown that, despite the presence of lytic CD8+ T cells in the
liver, factor IX expression was sustained and comparable in AAV-
immunized and naı¨ve animals [12–15]. So far only, the adoptive
transfer of AAV-cap specific CD8 T cells obtained from
immunized Balb/c mice and expanded in vitro together with
in vivo LPS stimulation after has been shown to reduce AAV-
mediated transgene expression due to hepatocytes elimination
[16]. Altogether these data suggest that features unique to the
human immune system, compared to lower mammals may
account for the difference in outcome of gene transfer observed
in the clinic compared to preclinical results [17].
A comparative analysis of luciferase expression between animal
receiving AAV8-luc alone in combination with AAV8-IL12
showed that no effect was seen very early after viral infection
(day 1) when very little expression, if any, is coming from stabilized
genomes, but later on, during the formation of transcriptionally
active forms, IL-12 clearly downregulates transgene expression. In
particular IFN-c produced by IL-12-activated NK and T cells
significantly down-regulates AAV mediated transgene expression,
reaching only 10% of the expression levels of the animal injected
with the reporter virus alone. In agreement with the in vivo data we
observed a significant 10-fold reduction of messenger RNA and
protein levels, however, no differences in vector genome copy
numbers. These data suggest that liver inflammation has no effect
on AAV8 entry into the cell or nucleus, but rather it interferes with
a post-entry step. Furthermore, IL-12 expression in the liver once
the AAV is transcriptionally stable has no effect over transgene
expression indicating no inhibition of promoter activity. Taken
together, our results suggest that IFN-c interferes with AAV
transcription.
Interestingly, we consistently found that the levels of luciferase
expression after the administration AAV8-luc alone was approx-
imately 10 times higher in IFN-cR and RAG deficient mice than
in WT mice. It has been recently reported that AAV injection
induced IL-12 production through activation TLR9, thus our
results might indicate that IFN-c production induced by IL-12
after AAV-mediated TLR9 activation reduced AAV-mediated
transgene expression in WT animals [18]. In fact, It remains to be
determined if lower transgene expression in WT animals when
compared to TLR9 KO mice is due to a lower number of viral
genomes or to a mechanism of transcriptional inhibition, this
would provide more evidences of the possible relationship between
liver inflammation and silencing of AAV-mediated transgene
expression. Furthermore, we cannot discard a role for type-I IFNs,
which have been frequently associated with regulation of gene
expression, however, attending to the work recently published by
Suzuki et al., rAAV vectors are poor inducers of type I IFNs [19].
The biological actions of IFN-c are characterized by both the
activation and the inhibition of gene transcription. Unfortunately,
in contrast to gene activation, the mechanisms through which the
cytokine suppresses gene transcription remain largely unclear.
Previous studies performed by our group showed that IL-12
expression using an inducible system down-regulates the expres-
sion of the inducible promoter itself, and this effect can be partially
reversed by treatment with a histone deacetylase inhibitor [11].
However, our results show that treatment with the histone
deacetylase inhibitor trichostatin A has no effect, while the
administration of the demethylating agent 5-aza-29-deoxycytidine
abolished IL-12-induced down-regulation of AAV-mediated
transgene expression. These data suggest that IFN-c alters the
expression of a cell factor (or factors) throughout DNA methyl-
ation, which is important for the formation of transcriptionally
active forms of AAV vector genomes. Additional studies are
required to determine which is the mechanism induced by IFN-c
that reduced the transcriptional activity of AAV genomes.
Recently, Breous and colleagues developed a mouse model that
mimics a scenario in which a subject that has received hepatic
AAV-mediated gene transfer develops subsequent systemic
inflammation. To do so, AAV injected animals received an
adenovirus expressing the same or an irrelevant antigen in
combination with several doses of TLR ligands. They found that
the inflammation induced by this treatment inhibits AAV-
mediated expression of transgenes in mouse liver [20]. However,
their data indicate that the loss of AAV mediated transgene
expression required a T cell response, most likely directed against
adenoviral proteins, which in turn eliminated a significant
percentage of AAV transduced hepatocytes. Similar results were
previously published by Washburn and colleagues, who induced
liver inflammation after AAV injection by using an adenovirus
expressing LIGHT, a member of the TNF superfamily that is a
potent co-stimulator of T cells [21]. Also in this study, it was
unclear whether the disappearance of AAV mediated gene
expression was due to a response against the adenovirus or to a
direct effect over AAV genomes. Nonetheless these results are in
agreement with our data, as the strong inflammatory reaction
produced by TLR ligands or adenovirus injection has no direct
effect over AAV mediated transgene expression [20] [21].
In conclusion, this work indicates that long-term AAV-mediated
transgene expression will not be affected by the development of an
inflammatory process, which may occur as a result of a viral
infection or due to underlying diseases causing liver inflammation
[22]. However, our work suggests that down-regulation of
transgene expression following AAV mediated gene transfer could
results from expression of pro-inflammatory cytokines and
consequent interference with vector genome stabilization early
on after gene delivery. This may not lead to loss of transduced
hepatocytes but may result in lower levels of transgene expression.
For this reason, before AAV administration, it will be crucial to
assess the baseline levels of inflammation in the target tissue, in this
case the liver. This is important particularly because many
disorders under consideration for hepatic gene transfer, such as
chronic hepatitis infection or hepatic genetic disorders, like a1-
antitripsin deficiency, present with some levels of underlying liver
disease, which may reduce efficiency of liver-derived transgene
expression. In these cases the use of an anti-inflammatory
treatment should be carefully evaluated in order to increase vector
transduction efficiency.
Materials and Methods
Animals and Animal Manipulation
Experiments were performed with 6–8 weeks-old female
C57BL/6 purchased from Harlan Laboratories (Barcelona,
Spain), knockout mice for the a chain of the IFN-c receptor
(IFNcR KO mice), RAG-1-deficient (RAG12/2) mice, CD1d-
deficient (CD1d2/2) mice and RAG2/2 cc2/2 mice. Mice
were bred and maintained under pathogen-free conditions in the
animal facility of the University of Navarra. The experimental
design was approved by the Ethical Committee for Animal Testing
of the University of Navarra. Mice were injected intravenously
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with the AAV viruses. For all procedures, animals were
anesthetized by intraperitoneal (IP) injection of a mixture of
xylacine (Rompun 2%, Bayer) and ketamin (Imalgene 50, Merial)
1:9 v/v. Blood collection was performed by bleeding in the retro-
orbital plexus, and serum samples were obtained by supernatant
recovery after centrifugation of total blood. Doxicycline treatment
for the induction of the AAV8-TetON-IL-12 vector, was
performed by a first IP injection of 50 mg/kg of doxycycline
(Sigma) followed by oral administration of a mixture of 2 mg/ml
of doxycycline with a 5% of sucrose for 6 days. Treatment with 59-
Azacytidine (Sigma) was administered by IP injection of 1 mg/Kg
every 24 hours. For the inhibition of histone deacetylation, 2 mg/
kg of trichostatin A (Alomon Laboratories) were injected IP every
48 hours. Dexamethasone was administered IP at a dose of
10 mg/kg one day before and the same day of vector injection, at
a dose of 5 mg/kg 1 and 2 days after vector injection, and at a
dose of 1 mg/kg the following days.
Animals were euthanized by cervical dislocation after being
anesthetized at the indicated time points. Liver samples were
collected for histological analysis and for nucleic acid and protein
extraction.
Viral Constructs and Vector Production and Purification
Recombinant AAV vectors were constructed with a transgene
cassette encoding the IL-12 single chain [9] or the reporter gene
luciferase under the regulation of a chimeric liver specific
promoter composed of the human a1-antitrypsin promoter
(AAT) with regulatory sequences from the albumin enhancer
(Ealb) [23]. The transgene cassette was flanked by AAV2 wild type
inverted terminal repeats. rAAV8 vectors with wild-type AAV2
ITRs were produced by polyethylenimine (PEI) mediated
cotransfection in HEK-293 cells. For each production a mixture
of plasmids, 20 mg of pro-AAV plasmid and 55 mg pDP8.ape
(PlasmidFactory GmbH & Co. KG, Bielefeld Germany), was
transfected into 293 T cells 15 cm plate using linear PEI 25 kDa
(Polysciences, Warrington, PA, USA) as described [9]. The cells
were harvested 72 hr after transfection and virus was released
from the cells by three rounds of freeze–thawing. Crude lysate
from all batches was then treated with Benzonase (50U/ml crude
lysate) for 1 hr at 37uC and then kept at 280uC until purification.
Purification of crude lysate was performed by iodixanol gradients
according to the method of Zolotukhin and colleagues [24]. The
purified batches were concentrated and diafiltrated by cross-flow
filtration (Spectrum Laboratories, Rancho Dominguez, CA) with a
molecular mass cut-off of 400 kDa. The batches were then
concentrated further by passage through Centricon tubes (YM-
100; Millipore, Bedford, MA) to a final concentration of
161012 vg/ml, as determined by quantitative polymerase chain
reaction (q-PCR). After concentration, the viral batches were
filtered (pore size, 0.22 mm) and stored at 280uC. Viral titers in
terms of genome copies per milliliter were determined by Q-PCR,
performed three times in triplicate at three different dilutions.
The adenovirus expressing AAV8 capsid proteins was produced
as described [10].
Bioluminescence Imaging
Mice were immobilised with IP anesthesia (a mixture of xylacine
and ketamine). The substrate D-luciferin (150 mg/kg dissolved in
phosphate-buffered saline; Promega, Madison, USA) was injected
IP. Ten minutes later, animals were placed in the dark chamber
for light acquisition in an IVIS CCD camera system (Xenogen)
and analysed with the Living Image 2.20 software package
Figure 5. Anti-inflammatory treatment blocks the IFN-c inhibitory effect. C57BL/6 mice received 2.561011 vg/kg of AAV8-luc vector alone
or in combination with 1.56109 vg/kg of AAV8-IL12 vector. Two groups of 5 mice each were injected with AAV8-luc or AAV8-luc in combination with
AAV8-IL12 and received Dexamethasone (Dex) as described in methods. Luciferase expression levels were analyzed in both groups of animals at days
1, 4, and 7 using a Xenogen in vivo luminometer. Luciferase expression was quantified and represented as photons/second. The data are shown as
mean 6 standard deviation (SD). The differences in luciferase expression were statistically evaluated by Student t test (ns, not significant).
doi:10.1371/journal.pone.0067748.g005
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(Xenogen). A region of interest (ROI) covering the whole animal
was defined, and quantification of light emission was performed in
photons/second. The same ROI was used for all the animals in
the different experiments. Time exposure ranged from 1 second to
5 minutes depending on light intensity.
Luciferase Measurement
Organ sections were frozen in liquid nitrogen until processed.
Tissue was homogenised in Luciferase Lysis Reagent (Promega).
Samples were centrifuged 15 sec at 12000g. Supernatant was
collected and measured in a tube luminometer (Lumat LB 9507,
from EG&G Bathold). Total proteins were quantified using the
Bradford assay using bovine serum albumin as a standard
(Thermo Scientific).
NK Depletion
Mice were NK-depleted by IP administration of 500 mg of the
anti-mouse NK1.1 antibody (PK136, BioXcell) 2 days before virus
injection and every 48 hours. Depletion levels of circulating NK
cells were determined to be .98% by flow cytometry of whole
blood.
Determination of IL-12 and IFN-c
Serum concentrations of murine IL-12 and IFN-c were
determined using OptEIA Mouse IL-12 (p70) and Mouse IFN-c
ELISA Kits (BD Bioscience-Pharmigen, San Diego, CA) accord-
ing to manufacturer’s instructions.
Determination of Serum Levels of AST and ALT
Alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) serum levels were analyzed in a Hitachi Automatic
Analyzer (Boehringer Mannheim, Indianapolis, IN).
Total DNA and RNA Extraction
To quantify the number of viral genomes, total DNA (tDNA)
was extracted from frozen livers using the QIAamp DNA Mini Kit
(Qiagen) following the manufacturer’s instructions. To analyze
transgene expression, total RNA was isolated from frozen livers
Figure 6. IL-12 has no effect over AAV-mediated stable expression. A) C57BL6 were intravenously injected with an AAV5-luc vector at a dose
of 2.561013 vg/kg, 21 days later luciferase expression was measured (day 21) and one day (day 0) later animals (n = 5) received an intravenous
injection of AAV8-IL12 or AAV8-iRFP at a dose of 1.56109 vg/kg. Luciferase expression levels were analyzed in both groups of animals at days 1, 4, 7,
and 14 using a Xenogen in vivo luminometer. Luciferase expression was quantified and represented as photons/second. The data are shown as mean
6 standard deviation (SD). The differences in luciferase expression were statistically evaluated by Student t test (ns, not significant). B) IFN-c
expression levels in serum were analyzed by ELISA at days 1, 4, 7 and 14. C) Animals were sacrificed 14 days after AAV8-IL12 and AAV8-iRFP injection.
Total DNA and RNA were isolated from liver and vector genome copies and luciferase messenger RNA (mRNA) copies were determined using a q-PCR
specific to luciferase, normalized to GADPH copy numbers. Values corresponding to the mean copy number from five animals.
doi:10.1371/journal.pone.0067748.g006
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using the TRIzol Reagent (Invitrogen) according to manufactur-
er’s instructions. Both nucleic acids were quantified after
extraction.
Viral Genome and Transgene Expression Quantification
Extracted RNA was pre-treated with DNAse I (Invitrogen) and
retro-transcribed into complementary DNA (cDNA) using M-
MLV reverse-transcriptase (Invitrogen). Copies of luciferase in
tDNA and cDNA were analyzed by quantitative PCR (qPCR)
using iQ SYBR Green Supermix (BioRad) in a CFX96 Real-Time
Detection System (BioRad). All data were normalized to GAPDH
(Glyceraldehyde-3-phosphate deshidrogenase) and primers used
were: GAPDH 39- TGCACCACCAACTGCTTA, GAPDH 59-
GGATGCAGGGATGATGTTC, Luciferase 39- TCTGAG-
GAGCCTTCAGGATT, Luciferase 59- TTTTGGCGAAGAAG-
GAGAAT.
Histology and Immunohistochemistry
Liver sections were fixed in 4% paraformaldehyde (Panreac),
embedded in paraffin, sectioned (3 mm), and stained with
hematoxylin and eosin. Sections were mounted and observed by
light microscopy.
Quantification of Specific IFN-c Producing Cells by
ELISpot Assay
Splenocytes were isolated as previously described [9]. Briefly,
spleens were mechanically disrupted and, after centrifugation, red
blood cells were lysed using ACK lysing buffer. Cells obtained
were resuspended in complete medium (RPMI-1640 supplement-
ed with 10% of fetal bovine serum, 1% of Penicillin/Streptomycin
and L-Glutamine). The AAV8 VP1 capsid peptide library was
generated as 15-mers overlapping by 12 amino acids (Mimotopes);
we separated the AAV-8 peptide library into 15 consecutive pools
each containing 10 peptides for the analysis, except pool number
15 that contains 6 peptides. Splenocytes (56105 cells/per well)
obtained were seeded in each ELISpot well in complete medium
and stimulated for 24 h at 37uC and 5% CO2 with pools of
peptides (2 mg/ml each), with a previously described H2b epitope
from AAV8 capsid protein NSLANPGIA (5 mg/ml) (Sabatino),
with PMA plus ionomycin (0.05 mg/ml and 1 mg/ml, respectively)
for positive controls or in absence of peptides for negative controls.
The interferon (IFN)-c ELISpot assay was performed according to
the manufacturer’s instructions (BD Biosciences, San Jose, CA).
The number of spots corresponding to IFN-c secreting cells was
determined using an ELISpot automatic reader (Immunospot
CTL, Germany). Samples were scored positive if numbers of
spots/well in presence of the peptide pools were .3 times higher
than number of spots/well that were cultured without peptides
and if numbers of spots in experimental wells were at least 3 SD
above those in control wells.
Statistical Analysis
The data are presented as mean values 6 standard deviation
and all data were analyzed for significance by the Student t test
(p,0.05 was considered significant) with the GraphPad Prism 5.0
software.
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